Home > Press > Merger of the subsidiary "Biopharm-engineering" AD into "Sopharma" AD

Merger of the subsidiary "Biopharm-engineering" AD into "Sopharma" AD

26 October 2022

Sofia, Bulgaria, October 26, 2022 – According to the requirements of art. 100t of LPOS, “Sopharma” AD notifies that the Board of Directors of "Sopharma" AD adopted a decision to initiate a procedure for the merger of the subsidiary "Biopharm-Engineering" AD, UIC: 119055339 in "Sopharma" AD under the conditions and in accordance with Chapter XVI of the Commercial Law and Art. 122 of the Law on the Public Offering of Securities. At the start of the procedure Sopharma AD owns 97.15% in the capital of the company.